{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:33:52Z","timestamp":1790411632002,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.eururo.2004.05.008","type":"journal-article","created":{"date-parts":[[2004,7,24]],"date-time":"2004-07-24T14:25:55Z","timestamp":1090679155000},"page":"488-495","source":"Crossref","is-referenced-by-count":193,"title":["Efficacy and Safety of Long-Term Treatment with the Dual 5\u03b1-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia"],"prefix":"10.1016","volume":"46","author":[{"given":"Frans","family":"Debruyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Barkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter van","family":"Erps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2004.05.008_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eururo.2004.05.008_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib3","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eururo.2004.05.008_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","article-title":"A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Djavan","year":"1999","journal-title":"Eur Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-5347(01)66461-9","article-title":"Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men","volume":"155","author":"Jacobsen","year":"1996","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","article-title":"Natural history of prostatism: risk factors for acute urinary retention","volume":"158","author":"Jacobsen","year":"1997","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib7","first-page":"248","article-title":"Long-term (92-month) natural history of changes in lower urinary tract symptom severity","volume":"86","author":"Jacobsen","year":"2000","journal-title":"BJU Int."},{"key":"10.1016\/j.eururo.2004.05.008_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0090-4295(01)01298-5","article-title":"Natural history of benign prostatic hyperplasia","volume":"58","author":"Jacobsen","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000474138","article-title":"Three-year follow up of a community based cohort of men with untreated benign prostatic hyperplasia","volume":"30","author":"Lee","year":"1996","journal-title":"Eur Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0090-4295(99)00209-5","article-title":"Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia","volume":"54","author":"Bruskewitz","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","article-title":"5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study","volume":"160","author":"Flanigan","year":"1998","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5347(05)68563-1","article-title":"Incidence rates and risk factors for acute urinary retention: the health professionals follow up study","volume":"162","author":"Meigs","year":"1999","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-4295(98)00666-9","article-title":"Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group","volume":"53","author":"Hudson","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0090-4295(02)01971-4","article-title":"Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia","volume":"60","author":"Vaughan","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.05.008_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-5347(01)62141-4","article-title":"Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate","volume":"161","author":"Span","year":"1999","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2004.05.008_bib17","first-page":"1496","article-title":"Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR","volume":"282","author":"Bramson","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"10.1016\/j.eururo.2004.05.008_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1569-9056(03)80637-1","article-title":"Dutasteride, a novel dual 5alpha-reductase inhibitor, reduces serum DHT to a greater extent than finasteride and achieves finasteride maximal reduction in a larger proportion of patients","volume":"2","author":"Roehrborn","year":"2003","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2004.05.008_bib19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J. Urol."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283804003240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283804003240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T12:24:02Z","timestamp":1549369442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283804003240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0302283804003240"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2004.05.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}